GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

Centers for Disease Control and Prevention. General
Recommendations on Immunization. Recommendations of the
Advisory Committee on Immunization Practices (ACIP).
MMWR. 2006 Dec 1;55(No. RR-15):1-48.
Centers for Disease Control and Prevention. Guidelines for
Prevention and Treatment of Opportunistic Infections in HIV-
Infected Adults and Adolescents. Recommendations from CDC,
the National Institutes of Health, and the HIV Medicine
Association of the Infectious Diseases Society of America.
MMWR. 2009 Apr 10;58(No. RR-4):1-207.
Centers for Disease Control and Prevention. Recommended Adult
Immunization Schedule – United States, 2010. MMWR. 2010 Jan
15;59(No. 1):1-4.
Geretti AM on behalf of the BHIVA Immunization Writing
Committee. British HIV Association guidelines for immunization
of HIV-infected adults 2008. HIV Medicine. 2008; 9: 795-848.
Anderson KB, Guest JL, Rimland D: HCV co-infection increases
mortality in HIV-infected patients in the highly active
antiretroviral therapy era: data from the HIV Atlanta VA Cohort
Study. Clin Infect Dis. 39(10), 1507-1513 (2004).
Bonacini M; Lin HJ; Hollinger FB. Effect of coexisting HIV-1
infection on the diagnosis and evaluation of hepatitis C virus. J
Acquir Immune Defic Syndr. 2001 Apr 1;26(4):340-4.
Strader DB; Wright T; Thomas DL; Seeff LB. Diagnosis,
management, and treatment of hepatitis C. Hepatology. 2004
Apr;39(4):1147-71.
Benhamou Y; Bochet M; Di Martino V; Charlotte F; Azria F;
Coutellier A; Vidaud M; Bricaire F; Opolon P; Katlama C; Poynard
T. Liver fibrosis progression in human immunodeficiency virus
and hepatitis C virus coinfected patients. The Multivirc Group.
Hepatology 1999 Oct;30(4):1054-8.
Puoti M; Bonacini M; Spinetti A; Putzolu V; Govindarajan S;
Zaltron S; et al. Liver fibrosis progression is related to CD4 cell
depletion in patients coinfected with hepatitis C virus and human
immunodeficiency virus. J Infect Dis. 2001 Jan 1;183(1):134-7.
Epub 2000 Nov 16.
Sterling RK; Contos MJ; Sanyal AJ; Luketic VA; Stravitz RT;
Wilson MS; Mills AS; Shiffman ML. The clinical spectrum of
hepatitis C virus in HIV coinfection. J Acquir Immune Defic
Syndr. 2003 Jan 1;32(1):30-7.
Rullier A; Trimoulet P; Neau D; Bernard PH; Foucher J; Lacoste
D; Winnock M; Urbaniak R; Ballardini G; Balabaud C; Bioulac-
Sage P; Le Bail B. Fibrosis is worse in HIV-HCV patients with lowlevel
immunodepression referred for HCV treatment than in
HCV-matched patients. Hum Pathol. 2004 Sep;35(9):1088-94.
Zdilar, D, Franco-Bronson, K, Buchler, N, et al. Hepatitis C,
interferon alfa, and depression. Hepatology. 2000; 31:120.
Poynard, T, Bedossa, P, Opolon, P. Natural history of liver fibrosis
progression in patients with chronic hepatitis C. Lancet.1997;
349:825.
Pol, S, Artru, P, Thepot, V, et al. Improvement of the CD4 cell
count after alcohol withdrawal in HIV-positive alcoholic patients.
AIDS.1996; 10:1293.
Falck-Ytter Y; Kale H; Mullen KD; Sarbah SA; Sorescu L;
McCullough AJ. Surprisingly small effect of antiviral treatment in
patients with hepatitis C. Ann Intern Med. 2002 Feb
19;136(4):288-92.
Vento S; Garofano T; Renzini C; Cainelli F; Casali F; Ghironzi G;
et al.Fulminant hepatitis associated with hepatitis A virus
superinfection in patients with chronic hepatitis C.N Engl J Med.
1998 Jan 29;338(5):286-90.
Pramoolsinsap C; Poovorawan Y; Hirsch P; Busagorn N;
Attamasirikul K. Acute, hepatitis-A super-infection in HBV
carriers, or chronic liver disease related to HBV or HCV. Ann Trop
Med Parasitol. 1999 Oct;93(7):745-51.
Recommended adult immunization schedule: United States,
2009*. Ann Intern Med.2009 Jan 6;150(1):40-4.
Liaw YF; Yeh CT; Tsai SL. Impact of acute hepatitis B virus
superinfection on chronic hepatitis C virus infection. Am J
Gastroenterol. 2000 Oct;95(10):2978-80.
Thomas DL. Advances in HIV/HCV coinfection. In: Seeskin EP,
King E, McGuire S and O´Loughlin Gross T Ed. HIV/AIDS
Annual Update 2008. Rancho Mirage, CA: Postgraduate Institute
for Medicine and Clinical Care Options, LLC 2008. p. 159-170.
Saito H, Tada S, Nakamoto N, Kitamura K, Horikawa H, Kurita
S, et al. Efficacy of non-invasive elastometry on staging of hepatic
fibrosis. Hepatol Res. 2004; 29:97-103.
Ziol M, Handra-Luca A, Kettaneh A, Chistidis C. Mal F, Kazemi
F, et al. Non-invasive assessment of liver fibrosis by measurement
of stiffness in patients with chronic hepatitis C. Hepatology. 2005
Jan;41(1):48-54.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus
infection in HIV-infected patients. N Engl J Med. 2004; 351:438-
50.
Nuñez M, Miralles C, Berdún MA, et al. The PRESCO trial: role
of extended duration of therapy with pegylated interferon alfa-2a
plus weight-based ribavirin dose in 389 HCV/HIV co-infected
patients.8th International Congress on Drug Therapy in HIV
Infection, Glasgow 2006; PL13.1.
Sauleda S, Juarez A, Esteban JI, et al. Interferon and ribavirin
combination therapy for chronic hepatitis C in human
immunodeficiency virus-infected patients with congenital
coagulation disorders. Hepatology.2001; 34(5):1035-40.
Chung RT, Andersen J, Volberding P, Robbins GK, Liu T,
Sherman KE, et al. Peginterferon Alfa-2a plus Rbavirin versus
Interferon Alfa-2 a plus Riavirin for chronic Hepatitis C in HIV
Coinfected persons. N Engl J Med.2004 Jul 29;351(5):451-9.
Castera L, Verginol J, Foucher J, Le Bail B, Chantelop E, Haaser
M, et al. Prospective comparison of transient elastography,
Fibristest, APRI, and liver biops for the assessment of fibrosis in
chronic hepatitis C. Gastroenterology.2005; 128:343-350.
Soriano V. Treatment of chronic hepatitis C in HIV-positive
individuals: selection of candidates.J Hepatol. 2006;44(1
Suppl):S44-8. Epub 2005 Dec.
National Institutes of Health Consensus Development
Conference Statement: Management of hepatitis C: 2002--June
10-12, 2002. Hepatology. 2002 Nov;36(5 Suppl 1):S3-20.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,
Goncales FL Jr, et al.Peginterferon Alfa-2a plus Ribavirin for
Chronic Hepatitis C Virus Infection. N Engl J Med. 2002 Sep
26;347(13):975-82.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman
M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial
treatment of chronic hepatitis C: a randomized trial. Lancet 2001,
Sep 22;358(9286):958-65.
Hammer SM, Eron JJ Jr, Reiss P et al.: Antiretroviral treatment of
adult HIV infection: 2008 recommendations of the International
AIDS Society-USA panel. JAMA. 300(5), 555-570 (2008).
Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M,
Lamoglia RS, et al.Baseline factors prognostic of sustained
virological response in patients with HIV–hepatitis C virus coinfection.
AIDS 2007, Jul 31;21(12):1555-9.
Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters
M, et al. Care of patients co-infected with HIV and HCV: 2007
updated recommendations from the HCV-HIV International
Panel. AIDS. 2007May 31;21(9):1073-89.
Lindahl K, Stahle L, Bruchfeld A, Schvarcz R: High-dose ribavirin
in combination with standard dose peginterferon for treatment of
patients with chronic hepatitis C. Hepatology. 2005
Feb;41(2):275-9.
Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K,
Ocampo A, et al.Role of weight-based ribavirin dosing and
extended duration of therapy in chronic hepatitis C in HIVinfected
patients: the PRESCO trial. AIDS Res Hum Retroviruses.
2007 Aug;23(8):972-82.
Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected
Person. Ann Intern Med, 2003;138(3):197-207.
Laguno M, Cifuentes C, Murillas J.et al.Randomized trial
comparing pegylated IFN-α-2b versus pegylated IFN-α-2a, both
plus ribavirin, to treat chronic hepatitis C in human
immunodefciency virus patients. Hepatology.2009;49(1):22-31.
Panel of the European AIDS Clinical Society (EACS). Guidelines
for the Clinical Management and Treatment of Chronic Hepatitis
B and C co-infection in HIV-infected Adults. European AIDS
Clinical Society; Jun 2008. The European AIDS Clinical Society
Site. Disponible en:
http://www.eacs.eu/guide/index.htmConsultado:15-09-2008.
Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers
DL: A comprehensive hepatic safety analysis of nevirapine in
different populations of HIV-infected patients.J Acquir Immune
Defic Syndr. 2003 Sep;34 Suppl 1:S21-33.
Chapman TM, Plosker GL, Perry CM: Fosamprenavir: a review of
its use in the management of antiretroviral therapy-naive patients
with HIV infection. Drugs. 2004;64(18):2101-24.
Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS
Clinical Society (EACS) guidelines for the clinical management
and treatment of chronic hepatitis B and C coinfection in HIVinfected
adults. HIV Med. 2008;9:82-88.
McGovern BH, Ditelberg JS, Taylor LE,et al. Hepatic steatosis is
associated with fibrosis, nucleoside analogue use, and HCV
182